# EDGAR Filing Document

**Accession Number:** 0001623526
**File Stem:** 0001193125-25-157116
**Filing Date:** 2025-7
**Character Count:** 2767
**Document Hash:** bdeffe83547112808eb874fca089dee8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-157116.hdr.sgml**: 20250811

**ACCESSION NUMBER**: 0001193125-25-157116

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250709

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Stoke Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001623526
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 471144582
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 45 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730
- **BUSINESS PHONE:** 781-430-8200

**MAIL ADDRESS:**
- **STREET 1:** 45 WIGGINS AVENUE
- **CITY:** BEDFORD
- **STATE:** MA
- **ZIP:** 01730

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ASOthera Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20141028

**STOKE THERAPEUTICS, INC.** 

45 Wiggins Avenue

Bedford, MA 01730

July 9, 2025

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Office of Life Sciences

Re: Stoke Therapeutics, Inc. Registration Statement on Form S-3 Filed July 9, 2025 File No. 333-288583

**<u>Via EDGAR - Acceleration Request</u>**

---

| | |
|:---|:---|
|  Requested Date: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;July 11, 2025 |
|  Requested Time: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4:00 p.m. Eastern Time |

---

Ladies and Gentlemen:

Stoke Therapeutics, Inc. (the "***Registrant***") hereby requests that the Securities and Exchange Commission (the "***Commission***") take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the "Requested Date" and "Requested Time" set forth above or as soon thereafter as practicable.

The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant's outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Forbess at (415) 875-2420 or, in her absence, to Mr. Freedman at (206) 389-4524.

\* \* \*

------

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| **STOKE THERAPEUTICS, INC.** | **STOKE THERAPEUTICS, INC.** |
| By: | /s/ Thomas Leggett |
|  | Thomas Leggett |
|  | Chief Financial Officer |

---

---

| | |
|:---|:---|
| cc: | Ian F. Smith, Interim Chief Executive Officer<br> Jonathan Allan, General Counsel<br> **Stoke Therapeutics, Inc.** |
|  | Robert A. Freedman, Esq.<br> Julia Forbess, Esq.<br> **Fenwick & West LLP** |

---